{
  "event_id": "2750bc0a427e",
  "ticker": "GSK",
  "company_name": "GlaxoSmithKline",
  "drug_name": "Nucala mepolizumab",
  "pdufa_date": "20250806",
  "approval_type": {
    "status": "found",
    "value": "bla",
    "source": "websearch:MENSA, DREAM trials",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T17:27:42.534699",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Severe eosinophilic asthma",
    "source": "websearch:MENSA, DREAM trials",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T17:27:42.534701",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "mepolizumab",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:43:48.137725",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Respiratory",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:58.764964",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Approved",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:43:48.137725",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:MENSA, DREAM trials",
    "confidence": 0.95,
    "evidence": [
      "MENSA, DREAM trials"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T17:27:42.534684",
    "error": null
  },
  "p_value": {
    "status": "found",
    "value": "<0.001",
    "source": "websearch:MENSA, DREAM trials",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T17:27:42.534692",
    "error": null
  },
  "p_value_numeric": 0.001,
  "effect_size": {
    "status": "found",
    "value": "53% reduction in exacerbation rate vs placebo",
    "source": "websearch:MENSA, DREAM trials",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T17:27:42.534695",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects With Severe Refractory Asthma",
    "MEA115588 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma"
  ],
  "nct_ids": [
    "NCT01691508",
    "NCT01691521"
  ],
  "enrollment": {
    "value": 135,
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2
  },
  "has_prior_crl": {
    "status": "found",
    "value": true,
    "source": "derived_from_resubmission",
    "confidence": 0.85,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": true,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:19:23.152711",
  "enriched_at": "2026-01-11T18:52:42.731034",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "6a3c012c7a99",
  "fda_designations": {
    "breakthrough_therapy": true,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": true,
    "accelerated_approval": false
  },
  "mechanism_of_action": "IL-5 inhibitor",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": "14-0"
  },
  "days_to_pdufa": -157,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:39.676194",
  "is_single_arm": {
    "value": false,
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "interventionModel=PARALLEL",
      "allocation=RANDOMIZED"
    ],
    "searched_sources": [
      "clinicaltrials.gov"
    ],
    "last_searched": "2026-01-11T08:31:09.636684",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "trial_region": {
    "value": "global",
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "countries=['MEXICO', 'NETHERLANDS', 'UNITED KINGDOM', 'POLAND', 'AUSTRALIA']..."
    ],
    "searched_sources": [
      "clinicaltrials.gov"
    ],
    "last_searched": "2026-01-11T08:31:09.636717",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:38:29.608647"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:38:29.608654"
  },
  "breakthrough_therapy": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T18:52:27.256457",
    "search_status": "CONFIRMED_NONE"
  },
  "orphan_drug": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "FDA Approves First Drug to Treat Group of Rare Blood ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T18:52:28.765030",
    "search_status": "FOUND"
  },
  "priority_review": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T18:52:34.596496",
    "search_status": "CONFIRMED_NONE"
  },
  "fast_track": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Nucala (mepolizumab) FDA Approval History - Drugs.com FDA approves drug to treat group of rare blood"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T18:52:36.126047",
    "search_status": "FOUND"
  },
  "accelerated_approval": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T18:52:42.731014",
    "search_status": "CONFIRMED_NONE"
  }
}